Abbisko Therapeutics’ Pimicotinib NDA Accepted by China NMPA for TGCT Treatment

Abbisko Cayman Limited ( (HK:2256) ) has provided an update.

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received acceptance from the China National Medical Products Administration (NMPA) for the New Drug Application (NDA) of pimicotinib, a CSF-1R inhibitor, for treating Tenosynovial Giant Cell Tumor (TGCT). This marks a significant milestone as pimicotinib is the first internally discovered drug by Abbisko to enter the NDA process, showing promising clinical efficacy and safety. The drug has received Priority Review and Breakthrough Therapy Designation in China, and similar recognitions in the US and EU, indicating its potential impact on the market and stakeholders. Abbisko has partnered with Merck for the global commercialization of pimicotinib, which demonstrated significant improvements in clinical trials presented at the 2025 ASCO Annual Meeting.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to the discovery and development of innovative medicines to address unmet medical needs both in China and globally. The company has developed a robust pipeline of programs in precision oncology and immuno-oncology, leveraging the expertise of experienced professionals from leading multinational pharmaceutical firms.

Average Trading Volume: 5,644,641

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.52B

For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.